Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $12.02 in the prior trading day, ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed at $11.77, down -2.08%. In other words, the price has decreased by -$2.08 from its previous closing price. On the day, 1.03 million shares were traded.
Ratios:
Our goal is to gain a better understanding of SPRY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.50 and its Current Ratio is at 12.54. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on February 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $40.
Raymond James Upgraded its Outperform to Strong Buy on August 13, 2024, whereas the target price for the stock was revised from $18 to $22.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 03 ’25 when Shawver Laura sold 50,000 shares for $12.31 per share. The transaction valued at 615,565 led to the insider holds 210,346 shares of the business.
Shawver Laura bought 50,000 shares of SPRY for $615,565 on Feb 03 ’25. On Jan 06 ’25, another insider, Shawver Laura, who serves as the Director of the company, sold 50,000 shares for $11.10 each. As a result, the insider received 555,065 and left with 210,346 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 445.09 while its Price-to-Book (P/B) ratio in mrq is 5.69.
Stock Price History:
Over the past 52 weeks, SPRY has reached a high of $18.51, while it has fallen to a 52-week low of $6.70. The 50-Day Moving Average of the stock is -4.09%, while the 200-Day Moving Average is calculated to be -2.10%.
Shares Statistics:
A total of 97.15M shares are outstanding, with a floating share count of 51.27M. Insiders hold about 47.24% of the company’s shares, while institutions hold 50.39% stake in the company.
Earnings Estimates
A comprehensive evaluation of ARS Pharmaceuticals Inc (SPRY) is underway, with the input of 3.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.12 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.16 and -$0.76 for the fiscal current year, implying an average EPS of -$0.57. EPS for the following year is -$0.35, with 3.0 analysts recommending between $0.6 and -$1.2.
Revenue Estimates
For the next quarter, 5 analysts are estimating revenue of $16.3M. There is a high estimate of $31M for the next quarter, whereas the lowest estimate is $4.1M.
A total of 5 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $59.07M, while the lowest revenue estimate was $6M, resulting in an average revenue estimate of $18.04M. In the same quarter a year ago, actual revenue was $30kBased on 5 analysts’ estimates, the company’s revenue will be $121.9M in the next fiscal year. The high estimate is $192.5M and the low estimate is $82.16M.
